Pharma & Biotech

Shares of Outlook Therapeutics have exploded higher since late March, surging roughly 950% after the FDA accepted the company’s regulatory...

The euphoria surrounding Bayer’s landmark victory before the US Supreme Court has propelled its shares to €48.40, a near-38% surge...

Outlook Therapeutics has escaped the threat of expulsion from the Nasdaq Capital Market, but the relief is tempered by a...

BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as...

Canopy Growth shareholders have had little to cheer about this year, but the past few days delivered two distinct catalysts...

Ocugen enters a make-or-break stretch that will test both its science and its stock. The gene therapy developer, which has...

The U.S. Supreme Court handed Bayer a landmark win on June 25, effectively closing the most potent legal avenue for...

A pair of catalysts is converging on Novo Nordisk just as the Danish drugmaker scrambles to expand its manufacturing footprint....

The Supreme Court’s 7–2 ruling excising thousands of Roundup claims from Bayer’s docket was the kind of event that sends...

Novo Nordisk’s stock has clawed back more than a third of its losses since the March 2026 trough, closing at...